Arcutis Biotherapeutics
ARQT
ARQT
207 hedge funds and large institutions have $1.79B invested in Arcutis Biotherapeutics in 2024 Q4 according to their latest regulatory filings, with 48 funds opening new positions, 60 increasing their positions, 65 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
10% more funds holding
Funds holding: 188 → 207 (+19)
0.03% more ownership
Funds ownership: 110.05% → 110.08% (+0.03%)
8% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 65
Holders
207
Holding in Top 10
6
Calls
$8.22M
Puts
$3.96M
Top Buyers
| 1 | +$35.8M | |
| 2 | +$21M | |
| 3 | +$17.5M | |
| 4 |
Millennium Management
New York
|
+$16.2M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$15.3M |
Top Sellers
| 1 | -$41M | |
| 2 | -$17.8M | |
| 3 | -$13.1M | |
| 4 |
PA
Perceptive Advisors
New York
|
-$12.6M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$12.3M |